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AbstrACt
Objectives Infections remain a threat for solid organ and 
stem cell transplant recipients. Antimicrobial prophylaxis 
and pre- emptive therapy have improved survival of these 
patients; however, the failure rates of prophylaxis are not 
negligible. The aim of this systematic review is to explore 
the reasons behind failure of antimicrobial prophylaxis and 
pre- emptive therapy.
setting This systematic review included prospective 
randomised controlled trials and prospective single- arm 
studies.
Participants The studies included were on prophylaxis 
and pre- emptive therapy of opportunistic infections 
in transplant recipients. Studies were included from 
databases MEDLINE, CENTRAL and Embase published until 
October first 2018.
Primary and secondary outcome measures Primary 
outcome measures were breakthrough infections, adverse 
events leading to stopping of treatment, switching 
medication or dose reduction. Secondary outcome 
measures were acquired resistance to antimicrobials, 
antifungals or antivirals and death.
results From 3317 identified records, 30 records from 
24 studies with 2851 patients were included in the 
systematic review. Seventeen focused on prophylactic 
and pre- emptive treatment of cytomegalovirus and seven 
studies on invasive fungal infection. The main reasons 
for failure of prophylaxis and pre- emptive therapy were 
adverse events and breakthrough infections, which were 
described in 54% (13 studies) and 38% (9 studies) of the 
included studies, respectively. In 25%, six of the studies, 
a detailed description of patients who experienced failure 
of prophylaxis or pre- emptive therapy was unclear or 
lacking.
Conclusions Our results show that although failure 
is reported in the studies, the level of detail prohibits 
a detailed analysis of failure of prophylaxis and pre- 
emptive therapy. Clearly reporting on patients with a 
negative outcome should be improved. We have provided 
guidance on how to detect failure early in a clinical 
setting in accordance to the results from this systematic 
review.
PrOsPErO registration number CRD42017077606.
IntrOduCtIOn
In spite of novel immunosuppressive regi-
mens and antimicrobial prophylaxis, infec-
tious complications remain a threat for 
solid organ and stem cell transplant (SCT) 
recipients.1–5 These patients are especially 
susceptible to opportunistic infections like 
cytomegalovirus (CMV), Pneumocystis jirovecii 
pneumonia (PCP), febrile neutropoenia, 
human herpesvirus 6 (HHV-6) and invasive 
fungal infections (IFI).1–5 Graft failure is a 
major risk of these opportunistic infections.6–8 
In recent years, organ transplantation and 
immunosuppressive regimes have developed 
greatly and thus become available for a wider 
patient population. This requires adequate 
antimicrobial prophylaxis guidelines and 
studies supporting the scientific evidence.
Antimicrobial prophylaxis and pre- emptive 
therapy are used as preventive measures; 
however, these vary notably among different 
transplant centres.9 10 This can be explained 
by differences in local setting and lack of 
strengths and limitations of this study
 ► To reduce selection bias, all the studies were inde-
pendently reviewed and risk of bias was assessed 
by two authors and disagreements solved by includ-
ing a third reviewer.
 ► One limitation of this systematic review is that the 
included studies were recruiting only adult patients.
 ► Inclusion of single- arm studies could be a potential 
limitation as these can cause bias in the systematic 
review.
 ► To reach a broad scope for the systematic review 
three databases, MEDLINE, Embase and CENTRAL, 
were searched.
 ► The systematic review was reported according to 
Preferred Reporting Items for Systematic Reviews 
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high level evidence in antifungal, antimicrobial and anti-
viral prophylaxis guidelines and fairly dated evidence for 
some infections like PCP and febrile neutropenia.5 11–14 
Although prophylaxis has proven to be a beneficial 
strategy, breakthrough infections and adverse events 
resulting in discontinuation of prophylaxis occur.15–17 
The rates of failure of prophylaxis have remained around 
10%–20% for opportunistic infections.15 18–20 In order 
to be able to optimise prophylaxis, it is important to 
understand underlying causes for failure. This systematic 
review will identify (1) causes of failure of prophylactic 
treatment, (2) factors that might contribute to failure of 
prophylaxis and (3) different approaches for adminis-
tering prophylaxis.
This systematic review aimed to summarise the main 
reasons why prophylaxis and pre- emptive therapy has 
failed in solid organ and allogeneic SCT recipients and 
how failure is reported in prospective studies. In this 




In this systematic review, we have defined failure of prophy-
laxis and pre- emptive therapy as stopping or changing the 
therapy during the study period for any stated reason. For 
example, failure could be a breakthrough infection, non- 
adherence, adverse events leading to stopping of therapy, 
etc. Even if some of the side effects could be anticipated, if 
this leads to stopping of therapy, it was defined as failure. 
We did not look into infections in the postprophylactic 
period.
search strategy and selection criteria
Methods of the analysis and inclusion criteria were spec-
ified in advance and documented in a protocol, which 
is available online: https://www. crd. york. ac. uk/ pros-
pero/ display_ record. php? RecordID= 77606 (online 
supplementary appendix 1). This report follows the 
Preferred Reporting Items for Systematic Reviews and 
Meta- Analyses (PRISMA) checklist (online supplemen-
tary appendix 2).21 This systematic review included 
prospective randomised controlled trials (RCT) and 
prospective single- arm studies from 1 January 2010 to 
1 October 2018. The starting date was 1 January 2010 
due to the changes in management of different infec-
tions in recent decades and to include the most recent 
evidence.11 12 There were no limitations for the patient 
setting, publication status and language. We analysed the 
failure during prophylaxis and pre- emptive therapy, thus 
the follow- up time varied. The review included patients 
(16 years and older) who had received either allogeneic 
stem cell, lung, kidney, liver, heart, pancreas or small 
bowel transplantation. Studies done on children under 
16 years were not included as this would have introduced 
more variability and require a separate analysis, thus 
were out with the scope of this review. Moreover, these 
patients were receiving trimethoprim/sulfamethoxazole 
for prophylaxis of PCP, ciprofloxacin for prophylaxis of 
febrile neutropenia, ganciclovir and/or valganciclovir for 
prophylaxis or pre- emptive- therapy of CMV and human 
herpesvirus 6 (HHV-6); or posaconazole or voriconazole 
or fluconazole or itraconazole for prophylaxis of inva-
sive fungal infections (IFI). Primary outcome measures 
were breakthrough infections, adverse events leading 
to stopping of treatment, switching medication or dose 
reduction. Secondary outcome measures were acquired 
resistance to antimicrobials, antifungals or antivirals and 
death.
To identify studies for this systematic review, the 
following databases were searched: MEDLINE (PubMed), 
EMBASE and Cochrane Central Register of Controlled 
Trials (CENTRAL). The search was performed on 1 
October 2018. The search strategy included MeSH terms 
and variations of transplant types, medications and 
prophylaxis (‘Antibiotic Prophylaxis’ (Mesh) OR antimi-
crobial OR antimicrobial) AND (Host OR Transplants 
OR Transplantation OR Transplant Recipients OR immu-
nocompromised OR transplant* OR kidney transplant*). 
The full- search strategies of all databases can be found 
in online supplementary appendix 3. The searches were 
done by AGM and MB. For screening, we used Covidence 
software ( www. covidence. org).
The literature search and data extraction for inclu-
sion and eligibility for this systematic review were done 
according to the inclusion criteria by AGM and MB 
independently. If there were discrepancies between the 
results, these were discussed and resolved with JWA or 
with consensus. If there was data missing or additional 
questions from the selected studies, then the authors of 
these studies were contacted. We excluded conference 
proceedings, retrospective studies, reviews, editorials and 
letters to the editor.
Outcomes, data extraction and quality
Data were extracted by AGM and independently checked 
by MB. Disagreement between reviewers was resolved by 
discussion with a third reviewer JWA. Data were extracted 
from each included trial on: characteristics of patients, 
type of intervention, study design, study population, 
outcome measurement, reasons for failure of prophylaxis 
or pre- emptive therapy (stopping of prophylaxis/pre- 
emptive therapy), main conclusions by authors, strengths 
and limitations (online supplementary appendix 4).
We considered performing a meta- analysis for our 
systematic review, however because the patient cohorts 
include different transplantations and varied interven-
tions, the studies were too heterogeneous, we decided 
to do a qualitative systematic review. The studies were 
divided into CMV and IFI prophylaxis and pre- emptive 
treatment groups.
Risk of bias in individual studies was assessed inde-
pendently by AGM and MB. For assessing bias in individual 
studies, Revised Cochrane risk- of- bias tool for randomised 
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Non- randomised Studies of Interventions (ROBINS- I) 
was used for prospective single- arm studies.22 23
rEsults
The search identified 3317 records for inclusion in the 
review. In total, 603 duplicate records were removed, and 
2543 records were excluded after screening of title and 
abstract. Full- text screening of 171 articles resulted in 24 
studies (in 30 articles) (PRISMA flow diagram in figure 1) 
to be included in the final review. We decided to exclude 
one full text in Japanese as it would not likely change the 
outcome of our systematic review. We contacted corre-
sponding authors of 24 studies (30 articles) for further 
information about reasons for preliminary stopping of 
prophylaxis and overall adherence to treatment, seven 
responded and three of those sent prespecified protocols; 
however, none provided additional information about 
failure of prophylaxis or pre- emptive treatment. The indi-
vidual study characteristics and risk of bias are presented 
in table 1.
We identified 24 studies including 2851 patients. Seven-
teen studies (11 RCTs15 24–38 and six single- arm39–46) with 
1952 subjects focused on CMV prophylaxis and seven 
studies (5 RCTs17 19 47–49 and 2 single- arm43 44) with 899 
subjects focused on IFI prophylaxis.
Of the 17 CMV studies, eight included only valganci-
clovir, two only ganciclovir, five included both valganci-
clovir and ganciclovir, two valaciclovir and valganciclovir. 
From all 17 CMV studies, seven focused only on prophy-
laxis, six only on pre- emptive therapy, three both on 
prophylaxis and pre- emptive therapy and one on prophy-
laxis and therapy.
The IFI studies varied with regard to study medication 
and patient group. Three studies evaluated fluconazole 
(comparison amphotericin B, anidulafungin and mica-
fungin), one posaconazole (comparison amphotericin 
B lipid complex), one itraconazole (comparison mica-
fungin) and two single- arm studies had voriconazole as 
study medication.
Failure of prophylaxis and pre-emptive therapy
No specific information about failure during prophylaxis 
or pre- emptive therapy was given in 25% (six studies: 
four being RCTs) of the included studies.19 25 28 40 42 47 50 
Four of these studies did record follow- up infections or 
long- term failure of prophylaxis therapy after cessation of 
prophylaxis19 40 42 47 and for one RCT the time- point was 
not specified.46
The most common reasons for failure of CMV prophy-
laxis (1524 study subjects) and CMV pre- emptive therapy 
(428 study subjects) were adverse events15 25 27 29 30 36 42 46 
and breakthrough CMV.15 29 41 42 46 For IFI prophylaxis 
(899 study subjects), it was adverse events19 43 44 48 49 and 
IFI.17 19 44 49 Overall, the adverse events and breakthrough 
infections were described in 54% (13 studies) and 38% 
(9 studies) of the studies respectively. In table 2, the 
reasons for stopping prophylaxis are described in detail. 
The detailed information about failure in the CMV (1506 
study subjects) and IFI (761 study subjects) RCT groups 
are summarised in figures 2 and 3.
From the secondary outcomes, death was reported 
more frequently—in 33% (n=8) of the studies, death 
was the reason for failure.17 27 30 31 35 36 44 46 The secondary 
outcome resistance to antimicrobials, antivirals and anti-
fungals was addressed in the introductions and discussions 
of the included studies, however not regarded as failure 
of therapy. Moreover, the presence and/or measure-
ment of resistance to the study drug was described in two 
studies.27 29 Boeckh et al report no resistance genes in the 
investigated patients and Palmer et al report one patient 
with known resistance to ganciclovir.
Not all identified cases of failure could be clarified even 
after contact with the authors of the studies. The reasons 
for stopping prophylaxis and pre- emptive therapy, patient 
reasons or physician or sponsor decision,27 29 were not explained 
in any of these studies. Moreover, in two studies,24 27 it 
was stated that prophylaxis was stopped because of other 
reasons. Adverse events, breakthrough infections and 
cause of death were mostly described in further detail 
in the included studies.15–17 27 29–31 35 42–44 46 48 49 However, 
reasons ‘other’,15 27 physician/investigator decision17 27 29 49 
and patients discretion15 were grouped together in studies 
and not described in detail.
Risk of bias across studies
Risk of bias was assessed using five domains for RCTs: 
randomisation, assignment and adherence to interven-
tion, measurement of outcome, missing data and selec-
tion of the reported results. For single- arm/observational 
studies domains were used: confounding, selection of 
participants, classification of interventions, missing data, 
measurement of outcomes and selection of the reported 
result. We concluded that all 16 RCTs and six single- arm 
had low risk of bias, three had some concerns and two 
had high risk of bias. Risk of bias in RCTs and single- arm 
studies is presented in tables 3 and 4.
dIsCussIOn
We aimed to explore the reasons why prophylaxis and pre- 
emptive therapy failed in transplant recipients. Twenty- 
four studies were included into this systematic review. We 
concluded that the main reason for stopping prophylaxis 
was adverse events for both CMV and IFI prophylaxis and 
CMV pre- emptive therapy. We did not observe notable 
differences between the prophylaxis and pre- emptive 
therapy groups. This result was expected as cessation of 
ganciclovir therapy is often described due to debilitating 
side- effects, especially bone marrow suppression,15 which 
is even more problematic in haematological patients.28 
Different antifungal agents have a diverse safety profile. 
Our results were also in line with the common side- effects 
of antifungals as we observed nausea and vomiting in 
azoles and nephrotoxicity in Amphotericin B as reasons 
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Figure 2 Failure of CMV prophylaxis and pre- emptive therapy in 11 RCTs (y- axis represents the proportion of the transplant 
group in percentages and x- axis represents transplant). CMV, cytomegalovirus; RCTs, randomised controlled trials.
Adverse events are known to be under- reported so the 
numbers that we summarised in this systematic review 
might be underestimated.51 52 A review by Golder et al52 
looked into different study designs and reporting of 
adverse events. The authors outlined that there is wide 
under- reporting of adverse events across different study 
designs and even more in the unpublished data. Unfortu-
nately, contacting the authors of the studies included in 
this systematic review did not result in additional informa-
tion about the reported adverse events. Meta- analysis was 
not done as the studies were too heterogeneous.
Surprisingly, reporting of failure was insufficient in 
25% of RCTs and 50% of prospective single- arm studies. 
One- fourth of the studies did not report on prelimi-
narily cessation of prophylaxis nor underlying reason. 
More worrisome was the fact that discontinuation of 
prophylaxis was mostly explained as adverse events and 
breakthrough infections, while patient and physicians’ 
discretion as reasons were grouped together. On the 
other hand, we observed that only five studies did record 
infections that occurred after the prophylaxis had been 
stopped. This is concerning, as in a clinical setting and in 
developing guidelines, it is important to make a distinc-
tion of breakthrough infections during and after prophy-
laxis and pre- emptive therapy.53 Also, it makes it more 
difficult to compare the efficacy of different medications, 
for example when using ganciclovir and letermovir.53 
Furthermore, one of the included RCTs17 reported early 
discharge from hospital as the main argument for stop-
ping of prophylaxis. In addition, some reasons were not 
clarified, for example physician and patient discretion 
were combined in two of the included studies. A system-
atic review published in 2018 explored the efficacy and 
safety of CMV prophylaxis; adverse events and break-
through infections were addressed, however the authors 
did not explicitly report additional information why 
patients stopped within these studies.54 Similarly, in a 
PCP prophylaxis systematic review, the authors described 
adverse events as reason for discontinuation while not 
mentioning adherence, resistance or patients’ choice.14
A systematic review about quality of reporting RCTs in 
medical oncology described that 79% of the adverse events 
in studies are reported according to Consolidated Stan-
dards of Reporting Trials (CONSORT) criteria, although 
the description of participants and preliminary stopping 
in each stage of the study was done correctly in only 59% 
of the studies.55 It has been argued that perhaps, poor 
reporting is deliberate to mask the shortcomings in study 
design.55 56 One may expect that in a prospective study, 
the patients are recruited and analysed prospectively 
thus the data about failure of prophylaxis like adverse 
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Figure 3 Failure of IFI prophylaxis in five RCTs (y- axis represents the proportion of the transplant group in percentages and 
x- axis represents transplant). For one study, 15% of failure was caused by patients discharged early, this has not been included 
in this figure. IFI, invasive fungal infection.
study protocols in clinical trial registers and following 
reporting guidelines helps consistent and more straight-
forward reporting of results.57 58 Goldacre and colleagues 
have looked into reporting of clinical trials specifically 
with regard to outcomes. They concluded that most of 
the studies did not have sufficient reporting—either 
outcomes were added or prespecified outcomes were not 
reported.59 These results raise concern to also whether 
failure is reported as per protocol. In our case, we faced a 
substantial quantity of missing data on failure and it is not 
always clear to us how studies were conducted with respect 
to exclusion of patients. An additional statement to the 
CONSORT criteria regarding better reporting of harms 
in randomised trials is a useful guidance document to 
improve conduct of studies and address shortcomings.60
According to our search criteria, we also planned to 
include studies looking into prophylaxis and pre- emptive 
therapy of PCP, HHV-6 virus and febrile neutropenia. 
Surprisingly, we were not able to identify suitable studies 
looking into prophylaxis of these infections for our system-
atic review. Current guidelines for the treatment of these 
infections use case reports, retrospective studies, surveil-
lance studies and outdated literature to give recommen-
dations.5 61 62 For instance, a systematic review focusing 
on PCP prophylaxis in non- HIV immunocompromised 
patients is used as main guidance of prophylaxis in this 
patient group; the studies included in this review date 
back from 1974 to 2008 (13 in the range 1977–1990).14 
Moreover, the prophylaxis of febrile neutropenia is 
widely supported by a systematic review that included 
studies with quinolones published from 1980 to 2010 (10 
in the range 1980–1997).13 Half of the studies in these 
reviews were published more than 20 years ago. Certainly, 
the evidence from these reviews are relevant to the field; 
however, the landscape of treatment of transplant recipi-
ents has changed—notably, with the emergence of resis-
tant pathogens63–66 and new data in today’s setting is 
needed to aid the update of clinical guidelines.62
As mentioned before, detailed data about failure of 
prophylaxis and pre- emptive therapy were lacking in some 
studies and no additional information was obtained when 
reaching out to the authors. Furthermore, a limitation 
of our study was the restriction of start date (1 January 
2010). This was done to avoid the effect of the signifi-
cant change in management of infections and focus on 
the most recent evidence.11 12 Another limitation is that 
we did not include studies about children. On the other 
hand, included studies already showed a heterogeneous 
variety of patient populations (eg, autologous and alloge-
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Selection of the 
reported result
Humar et al, 201015 + + + + + ?
Halim et al, 201631 ? + + ? + ?
Witzke et al, 201233 + + + ? + ?
Reischig et al, 201235 + + + ? + ?
Reischig et al, 201536 + + + ? + ?
Togashi et al, 201138 ? + + ? + ?
Padulles et al, 201625 + + + + + ?
Palmer et al, 201027 + + ? + + ?
Chawla et al, 201128 ? ? ? ? + ?
Boeckh et al, 201529 + + ? + + ?
Kim et al, 201030 ? + *+ ? + ?
Perrella et al, 201247 ? ? ? ? + ?
Winston et al, 201417 + + + + + ?
Chaftari et al, 201248 + ? ? ? + ?
Huang et al, 201219 + + ? ? + ?
Park et al, 201649 ? + + ? + ?
+low risk; ?, some concerns.
RCT, randomised controlled trials; RoB, risk- of- bias.















Montejo et al, 
201039
– ? + NI – ? NI
Nanmoku et al, 
201840
* + + + + ? NI
Perrottett et al, 
200941
* ? + ? * ? NI
McGillicuddy et 
al, 201042
* + + * * ? NI
Takenaka et al, 
201245
* ? + ? * ? NI
Park et al, 
201246
? + + ? + ? NI
Mitsani et al, 
201243
* ? + ? ? ? NI
Cordonnier et 
al, 201044
* * + ? ? ? NI
+, low risk; ?, moderate risk; *, serious risk; -, critical risk.
NI, no information; ROBINS, Risk of Bias in Non- randomised Studies of Interventions.
prophylaxis and pre- emptive therapy studies; therefore, 
we believe that adding paediatric studies would have 
further increased variability of our results.
There remains a variety of different practices between 
centres complicating patient transfers between hospitals.9 67 
We believe that having information about the discontinua-
tion of failure of prophylaxis and pre- emptive therapy could 
provide valuable information for guideline committees, 
medical practitioners and researchers conducting studies 
with these medications. Without this information, similar 
errors could be repeated in different studies.
There are several ways to predict failure in a clinical 
setting. Detecting adverse events and avoiding break-
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Figure 4 Detecting failure in a clinical setting. AE, adverse event.
patient or treating the physician. For example, using 
mobile applications for reporting adverse events,68 
defining the high- risk patients69 70 and therapeutic drug 
monitoring of potentially toxic medications.71
In figure 4, we have summarised guidance on how to 
detect failure early.68–76 As mentioned above, there are 
multiple studies that do not report the true breakthrough 
infections, only postprophylaxis infections are reported. 
In addition, we believe that defining the potential adverse 
events before and describing the method of measurement 
of these could increase adherence. Other supporting 
background from the current systematic review for this 
figure is presented in Appendix 5.
Conclusions
In general, RCTs and prospective single- arm studies about 
prophylaxis and pre- emptive therapy of opportunistic 
infections should provide more in- depth information 
about failure. The main reason why prophylaxis or pre- 
emptive therapy is stopped are adverse events; however, 
these may well be underreported. Thus, the management 
and reporting of adverse events is critically important and 
should be improved in clinical studies. In addition, our 
results suggest partially biased approach in the publica-
tion of clinical studies and therefore there are insuffi-
cient data to support evidence- based decision- making in 
prophylaxis of PCP, HHV-6 and febrile neutropenia.
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